Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (6): 903-908.doi: 10.19982/j.issn.1000-6621.20250512
• Review Articles • Previous Articles Next Articles
Yuan Nan1, Liu Yu1(
), Du Guichun2(
)
Received:2025-12-22
Online:2026-06-10
Published:2026-05-25
Contact:
Liu Yu,Du Guichun
E-mail:liuyu@cmu.edu.cn;rr2000n@126.com
Supported by:CLC Number:
Yuan Nan, Liu Yu, Du Guichun. Research progress on financial toxicity and its influencing factors in elderly patients with pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2026, 48(6): 903-908. doi: 10.19982/j.issn.1000-6621.20250512
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20250512
| [1] | World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024. |
| [2] | World Health Organization. The end TB strategy. Geneva: World Health Organization, 2015. |
| [3] | 李媛媛, 谢晶晶, 李树涛, 等. 2024年WHO全球结核病报告:全球与中国关键数据分析. 新发传染病电子杂志, 2024, 9(6): 92-98. doi:10.19871/j.cnki.xfcrbzz.2024.06.016. |
| [4] | 张灿有, 陈卉, 张慧, 等. 2011—2020年全国65岁及以上老年人肺结核报告发病情况分析. 中华疾病控制杂志, 2022, 26(11): 1252-1258. doi:10.16462/j.cnki.zhjbkz.2022.11.003. |
| [5] | 宋媛媛, 李涛, 夏辉, 等. 1997—2023年全国肺结核报告发病流行病学特征. 中国防痨杂志, 2024, 46(10): 1198-1208. doi:10.19982/j.issn.1000-6621.20240382. |
| [6] | Dong Z, Wang QQ, Yu SC, et al. Age-period-cohort analysis of pulmonary tuberculosis reported incidence, China, 2006—2020. Infect Dis Poverty, 2022, 11(1): 85. doi:10.1186/s40249-022-01009-4. |
| [7] | Di Gennaro F, Vittozzi P, Gualano G, et al. Active pulmonary tuberculosis in elderly patients: a 2016—2019 retrospective analysis from an italian referral hospital. Antibiotics (Basel), 2020, 9(8): 489. doi:10.3390/antibiotics9080489. |
| [8] | Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park), 2013, 27(2): 80-81, 149. |
| [9] | Valero-Elizondo J, Chouairi F, Khera R, et al. Atherosclerotic cardiovascular disease, cancer, and financial toxicity among adults in the United States. JACC CardioOncol, 2021, 3(2): 236-246. doi:10.1016/j.jaccao.2021.02.006. |
| [10] | Dau NQ, Kim D, Peled H. Reducing the risk of financial toxicity in the real-world setting for heart failure care. JACC Heart Fail, 2022, 10(11): 885. doi:10.1016/j.jchf.2022.06.015. |
| [11] | Patel MR. Financial toxicity in diabetes: The state of what we know. Curr Diab Rep, 2025, 25(1): 32. doi:10.1007/s11892-025-01588-0. |
| [12] | Prawitz AD, Garman ET, Sorhaindo B, et al. InCharge financial distress/financial well-being scale: development, administration, and score interpretation. J Financ Couns Plan, 2006, 17(1): 34-50. doi:10.1037/t60365-000. |
| [13] | 朱小玲, 王浪, 田艳珍, 等. 慢性病经济毒性量表的汉化及信效度检验. 医学新知, 2025, 35(8): 940-946. doi:10.12173/j.issn.1004-5511.202410161. |
| [14] | de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer, 2014, 120(20): 3245-3253. doi:10.1002/cncr.28814. |
| [15] | 于慧会, 毕雪, 刘运泳. 中文版癌症患者报告结局的经济毒性量表信度和效度研究. 中华流行病学杂志, 2017, 38(8): 1118-1120. doi:10.3760/cma.j.issn.0254-6450.2017.08.024. |
| [16] | 陈薇薇, 邹圣强, 袁嘉, 等. 中青年肺结核患者恐惧疾病进展的潜在剖面及影响因素分析. 中国防痨杂志, 2026, 48(1): 84-93. doi:10.19982/j.issn.1000-6621.20250284. |
| [17] | Dar MA, Chauhan R, Murti K, et al. Development and validation of subjective financial distress questionnaire (SFDQ): a patient reported outcome measure for assessment of financial toxicity among radiation oncology patients. Front Oncol, 2022, 11: 819313. doi:10.3389/fonc.2021.819313. |
| [18] | Khera N. Reporting and grading financial toxicity. J Clin Oncol, 2014, 32(29): 3337-3338. doi:10.1200/JCO.2014.57.8740. |
| [19] | 陈凤. 结直肠癌患者经济毒性的潜在类别及影响因素研究. 成都: 电子科技大学, 2025. doi:10.27005/d.cnki.gdzku.2024.006083. |
| [20] | Badr H, Han J, Mims M. Development and validation of FinTox: A new screening tool to assess cancer-related financial toxicity. Cancer Med, 2024, 13(15): e7306. doi:10.1002/cam4.7306. |
| [21] | Chen H, Bi H, Li P, et al. Evaluation of pulmonary tuberculosis disease burden in Shenyang, China, 2023. BMC Infect Dis, 2025, 25(1): 166. doi:10.1186/s12879-025-10572-8. |
| [22] | Fan S, Abulizi A, You Y, et al. Predicting hospitalization costs for pulmonary tuberculosis patients based on machine learning. BMC Infect Dis, 2024, 24(1): 875. doi:10.1186/s12879-024-09771-6. |
| [23] | Ghazy RM, El Saeh HM, Abdulaziz S, et al. A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients. Sci Rep, 2022, 12(1): 558. doi:10.1038/s41598-021-04345-x. |
| [24] | Ma X, Huang A, Chen H, et al. Household economic burden and catastrophic expenditures in non-resistant tuberculosis patients: cross-sectional survey in Guizhou, China. Front Public Health, 2025, 13: 1510195. doi:10.3389/fpubh.2025.1510195. |
| [25] | World Health Organization. Tuberculosis patient cost surveys: a handbook. Geneva: World Health Organization, 2017. |
| [26] | 张丽萍, 柳湘洁, 刘晓霞, 等. 武汉地区老年结核病耐药病例流行特征及疾病负担研究. 实用临床医药杂志, 2025, 29(6): 30-33. doi:10.7619/jcmp.20244924. |
| [27] | 李雪秋, 邝浩斌, 王挺, 等. 广州市耐多药肺结核患者自付医疗费用及影响因素分析. 中国防痨杂志, 2024, 46(4): 411-417. doi:10.19982/j.issn.1000-6621.20230448. |
| [28] | D’Silva OA, Lancione S, Ananthakrishnan O, et al. The catastrophic cost of TB care: Understanding costs incurred by individuals undergoing TB care in low-, middle-, and high-income settings-A systematic review. PLoS Glob Public Health, 2025, 5(4): e0004283. doi:10.1371/journal.pgph.0004283. |
| [29] | Long Q, Smith H, Zhang T, et al. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health, 2011, 11: 393. doi:10.1186/1471-2458-11-393. |
| [30] | 张馨月, 王瑜, 熊丽蓉. 1990—2021年中国耐多药结核病负担趋势及其危险因素分析. 现代预防医学, 2025, 52(9): 1544-1549. doi:10.20043/j.cnki.MPM.202412525. |
| [31] | 梁博文, 鲜馥阳, 李波, 等. 238例老年耐多药肺结核临床特点及不良治疗结局影响因素分析. 中国热带医学, 2024, 24(3): 276-281. doi:10.13604/j.cnki.46-1064/r.2024.03.08. |
| [32] | Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin, 2018, 68(2): 153-165. doi:10.3322/caac.21443. |
| [33] | 杨晓明, 陈海兰, 朱翠敏, 等. 老年肺结核患者负性情绪调查及影响因素分析. 国际精神病学杂志, 2025, 52(2): 606-609. doi:10.13479/j.cnki.jip.2025.02.023. |
| [34] | Samal J, Dehury RK, Thomas MB, et al. Prevalence and predictors of depression in tuberculosis patients in india: a systematic review and meta-analysis. Discov Ment Health, 2025, 5(1): 104. doi:10.1007/s44192-025-00248-9. |
| [35] | 杨文璐. 首发耐药结核病患者家庭抗逆力变化轨迹及其影响因素的纵向研究. 成都: 成都中医药大学, 2024. doi:10.26988/d.cnki.gcdzu.2024.000513. |
| [36] | 丁加琪, 闻俊, 孙馨, 等. 肺结核患者经济毒性的研究进展. 护理管理杂志, 2025, 25(8): 668-671, 685. doi:10.3969/j.issn.1671-315x.2025.08.005. |
| [37] | 张译友, 田媛, 帕孜来提·赛登 等. 脑卒中患者经济毒性现状及影响因素分析. 中国临床护理, 2023, 15(3): 183-186. doi:10.3969/j.issn.1674-3768.2023.03.013. |
| [38] | 陶继华. 膀胱癌患者经济毒性风险预测模型的构建及验证. 成都: 电子科技大学, 2025. doi:10.27202/d.cnki.gkmyc.2024.000944. |
| [39] | Filetti M, Lombardi P, Gentile G, et al. The financial toll of cancer: uncovering the links between financial toxicity and symptom burden. Oncologist, 2025, 30(6): oyaf131. doi:10.1093/oncolo/oyaf131. |
| [40] | 徐玲, 曾司甯, 郭子宁, 等. 脑卒中患者经济毒性潜在剖面分析及其影响因素研究. 军事护理, 2024, 41(4): 51-55. doi:10.3969/j.issn.2097-1826.2024.04.013. |
| [41] | 邹潘琳, 林丽桑, 谢宝缘, 等. 乳腺癌化疗患者经济毒性现状及影响因素. 吉林医学, 2024, 45(11): 2759-2763. doi:10.3969/j.issn.1004-0412.2024.11.048. |
| [42] | 沈雅琳, 汤利萍, 曹英, 等. 输尿管皮肤造口患者经济毒性状况及影响因素分析. 护理学杂志, 2022, 37(10): 26-29. doi:10.3870/j.issn.1001-4152.2022.10.026. |
| [43] | 季静芬, 黎萌, 伍雅琴, 等. 结直肠癌患者决策自我效能及智谋对其经济毒性的影响. 护理管理杂志, 2024, 24(6): 518-522. doi:10.3969/j.issn.1671-315x.2024.06.012. |
| [44] | He X, Chen J, Zhang L, et al. Identifying the factors affecting financial toxicity status in patients with middle and advanced colorectal cancer: a cross-sectional study. Front Public Health, 2024, 12: 1421314. doi:10.3389/fpubh.2024.1421314. |
| [45] | 况艺, 裘佳佳, 汤立晨, 等. 乳腺癌术后患者经济毒性水平及影响因素的纵向研究. 护士进修杂志, 2024, 39(19): 2023-2030. doi:10.16821/j.cnki.hsjx.2024.19.002. |
| [46] | Li Y, Chen L, Hao X, et al. Financial toxicity and its association with psychological distress and quality of life: Comparison between young, middle and old cancer patients. Psychooncology, 2025, 34(10): e70312. doi:10.1002/pon.70312. |
| [47] | Liu S, Xie Y, Li T, et al. Social support, quality of life, and financial toxicity among patients with hepatocellular carcinoma. J Hepatocell Carcinoma, 2025, 12: 1711-1723. doi:10.2147/JHC.S523284. |
| [48] | Kim S, Perry LM, Mossman B, et al. Financial burden and physical and emotional quality of life in COPD, heart failure, and kidney failure. PLoS One, 2024, 19(7): e0306620. doi:10.1371/journal.pone.0306620. |
| [49] | 张慧, 赵雁林, 严俊. 我国结核病预防控制进展与挑战. 中国预防医学杂志, 2025, 26(1): 1-7. doi:10.16506/j.1009-6639.2025.01.001. |
| [50] | 何裕畅, 叶志辉, 张秀莲, 等. 老年肺结核患者治疗的研究进展. 中国防痨杂志, 2025, 47(S1): 361-363. |
| [51] | Meghji J, Gregorius S, Madan J, et al. The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting. Thorax, 2021, 76(4): 387-395. doi:10.1136/thoraxjnl-2020-215338. |
| [52] | 何昱颖, 阮云洲, 陈玮, 等. 贵州省耐多药结核病定点医院耐多药肺结核患者直接医疗费用影响因素的广义线性模型分析. 微量元素与健康研究, 2023, 40(5): 73-76. |
| [53] | Lee S, Kim MJ, Lee SH, et al. Comparison of disability-adjusted life years (DALYs) and economic burden on people with drug-susceptible tuberculosis and multidrug-resistant tuberculosis in Korea. Front Public Health, 2022, 10: 848370. doi:10.3389/fpubh.2022.848370. |
| [54] | 韦柳迎, 荆玮, 刘志峰, 等. 含贝达喹啉方案治疗南宁市耐多药/利福平耐药肺结核患者成本效果分析:一项回顾性队列研究. 中国防痨杂志, 2025, 47(7): 914-920. doi:10.19982/j.issn.1000-6621.20240553. |
| [55] | Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8): 2230-2241.e11. doi:10.1053/j.gastro.2019.02.002. |
| [56] | 中华医学会结核病学分会. 老年肺结核诊断与治疗专家共识(2023版). 中华结核和呼吸杂志, 2023, 46(11): 1068-1084. doi:10.3760/cma.j.cn112147-20230921-00182. |
| [57] | Zhou M, Peng Y, Liu K, et al. Direct medical expenses and influencing factors of MDR/RR-TB in eastern China: Based on data from multi-hospital information systems. Risk Manag Healthc Policy, 2023, 16: 1955-1965. doi:10.2147/RMHP.S420082. |
| [58] | Lu L, Jiang Q, Hong J, et al. Catastrophic costs of tuberculosis care in a population with internal migrants in China. BMC Health Serv Res, 2020, 20(1): 832. doi:10.1186/s12913-020-05686-5. |
| [59] | Stracker N, Hanrahan C, Mmolawa L, et al. Risk factors for catastrophic costs associated with tuberculosis in rural South Africa. Int J Tuberc Lung Dis, 2019, 23(6): 756-763. doi:10.5588/ijtld.18.0519. |
| [60] | 张金萍, 周小平, 丁志伟, 等. 基于双重差分法的疾病诊断相关分组支付方式改革对肺结核患者住院费用影响的研究. 中国防痨杂志, 2025, 47(11): 1515-1521. doi:10.19982/j.issn.1000-6621.20250198. |
| [61] | 李改云, 吴杨昊天, 丁明峰, 等. 取消药品加成政策前后肺结核患者住院费用的中断时间序列分析. 中国防痨杂志, 2022, 44(10): 1071-1078. doi:10.19982/j.issn.1000-6621.20220220. |
| [62] | Zhang M, Wang X, Shao M, et al. Financial toxicity of informal caregivers of colorectal cancer patients: A cross-sectional study. Eur J Oncol Nurs, 2024, 69: 102519. doi:10.1016/j.ejon.2024.102519. |
| [63] | Fuady A, Anindhita M, Hanifah M, et al. Codeveloping a community-based, peer-led psychosocial support intervention to reduce stigma and depression among people with tuberculosis and their households in Indonesia: a mixed-methods participatory action study. NPJ Prim Care Respir Med, 2025, 35(1): 7. doi:10.1038/s41533-024-00407-5. |
| [64] | Gu C, Liu B, Wang H, et al. The chain-mediating roles of social support and depression in the relationship between tuberculosis knowledge and self-management: a cross-sectional study based on the ABC-X model. Front Public Health, 2025, 13: 1640626. doi:10.3389/fpubh.2025.1640626. |
| [65] | Ponnuchamy L, Majhi G, Shreedevi AU, et al. Post-intervention psychosocial outcomes among tuberculosis patients in India: The role of community engagement. Cureus, 2025, 17(11): e96064. doi:10.7759/cureus.96064. |
| [1] | Cheng Wen, Guo Lifang, Nie Wenjuan. Application, methods, and practice of therapeutic drug monitoring in individualized anti-tuberculosis therapy [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 882-891. |
| [2] | Hu Xinyang, Liu Yang, Gao Jingtao. Research progress on latent tuberculosis infection in patients with hematological malignancies [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 694-699. |
| [3] | Lai Xiaoyu, Liao Qinghua, Wen Wenpei, Guo Huixin, Lin Weibin, Chen Xunxun. Advances in the research on the pathogenesis of tuberculous uveitis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 716-622. |
| [4] | Qiu Yuxian, Huang Fang, Yang Xiaoyi, Yang Feng, Lu Hua, Zhang Tianyi, Zhang Yang, Yao Rong, Li Yuanyuan. Research progress in digital twin technology for tuberculosis patient management [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 550-555. |
| [5] | Cao Hong, Qian Bing, Zhao Kefu, Chen Lili, He Yuqin, Wu Jinju, Chen Shuangshuang, Xu Rui, Zhao Cunxi. Analysis of characteristics of pulmonary tuberculosis patients aged 60 and above in Hefei City, 2015—2024 [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 394-404. |
| [6] | Meng Qiuyue, Rong Ningning, Liu Yadong, Yang Haixia, Ma Mingli. Progress in interventions to improve treatment adherence among patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 413-418. |
| [7] | Ni Sheng, Sha Wei, Wang Li. Research progress on the mechanisms of lung injury caused by Mycobacterium abscessus [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 419-425. |
| [8] | Wang Xueyu, Chu Naihui, Nie Wenjuan. Research progress on the anti-Mycobacterium tuberculosis activity of sitafloxacin [J]. Chinese Journal of Antituberculosis, 2026, 48(2): 299-303. |
| [9] | Fu Yanan, Yang Xiaotao, Liu Xiaomei, Shen Adong. Research progress in drug-susceptible pulmonary tuberculosis treatment regimens for children [J]. Chinese Journal of Antituberculosis, 2026, 48(1): 148-152. |
| [10] | Wang Lin, Qu Yan. Research progress on hospital infection prevention and control of multidrug-resistant organisms [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1196-1203. |
| [11] | Lai Xiaoyu, Duan Hongfei, Chen Xunxun, Guo Huixin, Liao Qinghua, Chen Qian, Liang Dan. Clinical characteristics, diagnostic strategies, and advances in grading criteria for tubercular uveitis [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1204-1211. |
| [12] | Wang Huijuan, Cheng Ruixia, Xu jia. Research progress on medication adherence in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1212-1219. |
| [13] | Chen Liyao, Peng Xiao, Liu Yuanyuan, Shi Jin, Guo Yongli, Lu Jie. The molecular mechanisms of ferroptosis and their potential applications in the diagnosis and treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1227-1232. |
| [14] | Zhu Qingdong, Zhao Chunyan, Xie Zhouhua, Song Shulin, Song Chang. Research progress on the application of artificial intelligence-based CT radiomics in the diagnosis and treatment response monitoring of tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(8): 1068-1076. |
| [15] | Meng Qinglin, Wang Yunxia, Tang Yan, Liu Eryong. Analysis of psychological support of tuberculosis patients at home and abroad [J]. Chinese Journal of Antituberculosis, 2025, 47(8): 981-985. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.